Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm2(CAG-Notch2*)Uzs}
• Allele Name: targeted mutation 2, Ursula Zimber-Strobl
• Allele ID: MGI:5301613
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^+	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J	MGI:5301628
cn2	Gt(ROSA)26Sor^tm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor^+ Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J	MGI:5301629
cn3	Gt(ROSA)26Sor^tm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S6/SvEvTac * BALB/c * C57BL/6J	MGI:5301627

Genotype
MGI:5301628

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm2(CAG-Notch2*)Uzs}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

increased B cell proliferation ( J:179036 )

• slightly in vivo

• in vitro without stimulation and after stimulation with anti-CD40 antibodies or LPS

increased spleen weight ( J:179036 )

abnormal B cell differentiation ( J:179036 )

• B cell development in the spleen is altered

• however, mice exhibit normal B cell development in the bone marrow

decreased transitional stage T2 B cell number ( J:179036 )

• in the spleen

increased transitional stage T1 B cell number ( J:179036 )

• in the spleen

decreased B cell number ( J:179036 )

• in re-circulating B cells

• slightly in the spleen

decreased B-1a cell number ( J:179036 )

• in the peritoneal cavity

decreased B-2 B cell number ( J:179036 )

• in the peritoneal cavity

decreased follicular B cell number ( J:179036 )

• 5 times

increased T cell number ( J:179036 )

• doubled in the spleen

decreased spleen B cell follicle size ( J:179036 )

• diminished in size

decreased spleen germinal center number ( J:179036 )

• after NP-CGG stimulation with diminished NP-specific IgM and IgG1

abnormal spleen marginal zone morphology ( J:179036 )

• enlarged in size

increased marginal zone B cell number ( J:179036 )

• 7 times

decreased IgG1 level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

decreased IgG3 level ( J:179036 )

• after NP-Ficoll stimulation

decreased IgM level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

abnormal marginal zone B cell physiology ( J:179036 )

• enlarged in response to anti-CD40 antibodies and IL4

hematopoietic system

increased B cell proliferation ( J:179036 )

• slightly in vivo

• in vitro without stimulation and after stimulation with anti-CD40 antibodies or LPS

increased spleen weight ( J:179036 )

abnormal B cell differentiation ( J:179036 )

• B cell development in the spleen is altered

• however, mice exhibit normal B cell development in the bone marrow

decreased transitional stage T2 B cell number ( J:179036 )

• in the spleen

increased transitional stage T1 B cell number ( J:179036 )

• in the spleen

decreased B cell number ( J:179036 )

• in re-circulating B cells

• slightly in the spleen

decreased B-1a cell number ( J:179036 )

• in the peritoneal cavity

decreased B-2 B cell number ( J:179036 )

• in the peritoneal cavity

decreased follicular B cell number ( J:179036 )

• 5 times

increased T cell number ( J:179036 )

• doubled in the spleen

decreased spleen B cell follicle size ( J:179036 )

• diminished in size

decreased spleen germinal center number ( J:179036 )

• after NP-CGG stimulation with diminished NP-specific IgM and IgG1

abnormal spleen marginal zone morphology ( J:179036 )

• enlarged in size

increased marginal zone B cell number ( J:179036 )

• 7 times

decreased IgG1 level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

decreased IgG3 level ( J:179036 )

• after NP-Ficoll stimulation

decreased IgM level ( J:179036 )

• diminished NP-specific IgM and IgG1 after NP-CGG stimulation

abnormal marginal zone B cell physiology ( J:179036 )

• enlarged in response to anti-CD40 antibodies and IL4

growth/size/body

increased spleen weight ( J:179036 )

cellular

increased B cell proliferation ( J:179036 )

• slightly in vivo

• in vitro without stimulation and after stimulation with anti-CD40 antibodies or LPS

Genotype
MGI:5301629

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm2(CAG-Notch2*)Uzs}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19^tm1(cre)Cgn
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J

immune system

abnormal B cell differentiation ( J:179036 )

• T1 B cells do not proceed to T2 B cell stage but directly develop into marginal zone B cells

decreased transitional stage T2 B cell number ( J:179036 )

• in the spleen

increased transitional stage T1 B cell number ( J:179036 )

• in the spleen

decreased mature B cell number ( J:179036 )

• in the bone marrow

decreased follicular B cell number ( J:179036 )

decreased pre-B cell number ( J:179036 )

• in the bone marrow

abnormal spleen marginal zone morphology ( J:179036 )

• enlarged

increased marginal zone B cell number ( J:179036 )

hematopoietic system

abnormal B cell differentiation ( J:179036 )

• T1 B cells do not proceed to T2 B cell stage but directly develop into marginal zone B cells

decreased transitional stage T2 B cell number ( J:179036 )

• in the spleen

increased transitional stage T1 B cell number ( J:179036 )

• in the spleen

decreased mature B cell number ( J:179036 )

• in the bone marrow

decreased follicular B cell number ( J:179036 )

decreased pre-B cell number ( J:179036 )

• in the bone marrow

abnormal spleen marginal zone morphology ( J:179036 )

• enlarged

increased marginal zone B cell number ( J:179036 )

Genotype
MGI:5301627

cn3

• Allelic Composition: Gt(ROSA)26Sor^{tm2(CAG-Notch2*)Uzs}/Gt(ROSA)26Sor⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S6/SvEvTac * BALB/c * C57BL/6J

immune system

arrested B cell differentiation ( J:179036 )

• B cell development is blocked at pro-B cell stage

decreased B cell number ( J:179036 )

• in the spleen, inguinal lymph nodes, and peritoneal cavity

increased T cell number ( J:179036 )

decreased splenocyte number ( J:179036 )

hematopoietic system

arrested B cell differentiation ( J:179036 )

• B cell development is blocked at pro-B cell stage

increased bone marrow cell number ( J:179036 )

• slightly

decreased B cell number ( J:179036 )

• in the spleen, inguinal lymph nodes, and peritoneal cavity

increased T cell number ( J:179036 )

decreased splenocyte number ( J:179036 )